Update: June 10, 2019 – Video release of Construction
Profile Solutions, Inc. (OTC Pink: PSIQ) announces the formation of CannBerry Tek, Inc. as a Hi-tech innovative Biotechnology Company to manage various Research & Development (“R&D”) activities with the major focus on the Medical Cannabis industry.
CannBerry Tek, Inc. (“CannBerry”) has assembled a powerful highly experienced R&D management team to operate in Israel. During the initial phase, CannBerry intends to focus on generating and developing a unique man-made repository of seeds known as a Cannabis Genetic Seed Bank to create and secure rare, hard-to-find or difficult to legally obtain Cannabis seed types and varieties.
In that regard, CannBerry intends to apply unique proprietary technological tools developed by its management to monitor Cannabis under sterile conditions in a fully controlled environment. During the second phase, CannBerry intends to form unique Active Pharmaceutical Ingredient formulations to develop specific Cannabis-based products for the Medical Cannabis industry. An Active Pharmaceutical Ingredient is any substance or mixture of substances intended to be used in the manufacture of a drug (medicinal) product and that, when used in the production of a drug, becomes an active ingredient of the drug product. Such substances are intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure or function of the body. CannBerry’s mission is to become a leading supplier of superior genetics as well as Active Pharmaceutical Ingredients to the Cannabis industry. In order to reinforce its Product varieties and R & D capabilities, CannBerry intends to leverage its close relationships with leading Cannabis Research Centers to establish R & D Joint Ventures including but not limited to the Agricultural Research Organization – Volcani Center (http://www.moag.gov.il/en/About%20the%20Ministry/ministry_sites/Pages/agricultural_research_organization.aspx), Weizmann Institute of Science (https://www.weizmann.ac.il/pages/), Hebrew University Agriculture Faculty (https://en.hafakulta.agri.huji.ac.il/) and Technion’s Faculty of Medicine – Bruce Rappaport Faculty of Medicine (https://md.technion.ac.il/about/) and Tel Aviv University Agricultural Research Center.
Potential sources of income from the development of proprietary strains are (1) licensing of premium genetic strains (2) wholesale seed sales (3) clone fulfillment services (4) custom breeding programs and (5) tissue culture and strain patenting services.
Dan Oran, CEO of PSIQ stated, “By protecting the intellectual property associated with the genetics to be developed by CannBerry, PSIQ is positioning itself as a leader in the medical and recreational Cannabis markets. The strategy to breed innovative plants that encase the experience and flavor profiles into bud, oil, shatter and ingredients in branded products is what consumers demand and will make PSIQ unique & different. This breeding program is intended to be a revenue generator for PSIQ by offering strain development to cultivators around the world through the licensing of proprietary strains.”